These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21262425)

  • 61. Comparative studies on branded enoxaparin and a US generic version of enoxaparin.
    Walenga JM; Jeske WP; Hoppensteadt D; Cunanan J; Khan H; Escalante V; Fareed J; Bakhos M
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):261-7. PubMed ID: 23091283
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Survey of hospital policies regarding low-molecular-weight heparins.
    Schumock GT; Nutescu EA; Walton SM; Arondekar BV; Lewis RK
    Am J Health Syst Pharm; 2002 Mar; 59(6):534-8. PubMed ID: 11908246
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin.
    Liu X; St Ange K; Fareed J; Hoppensteadt D; Jeske W; Kouta A; Chi L; Jin C; Jin Y; Yao Y; Linhardt RJ
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):542-553. PubMed ID: 28056526
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Low-molecular-weight heparin.
    Wolf H
    Med Clin North Am; 1994 May; 78(3):733-43. PubMed ID: 8170267
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Generic low molecular weight heparins: a significant dilemma.
    Fareed J; Iqbal O; Nader H; Mousa S; Wahi R; Coyne E; Bick RL
    Clin Appl Thromb Hemost; 2005 Oct; 11(4):363-6. PubMed ID: 16244760
    [No Abstract]   [Full Text] [Related]  

  • 66. Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.
    Luna E; Agrawal P; Mehta R; Vernhes C; Viskov C; Amiral J; Warren WL; Drake DR
    Clin Appl Thromb Hemost; 2015 Apr; 21(3):211-22. PubMed ID: 25525049
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The therapeutic equivalence of complex drugs.
    Schellekens H; Klinger E; Mühlebach S; Brin JF; Storm G; Crommelin DJ
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):176-83. PubMed ID: 20951177
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
    Glauser BF; Vairo BC; Oliveira SN; Cinelli LP; Pereira MS; Mourão PA
    Thromb Haemost; 2012 Feb; 107(2):302-14. PubMed ID: 22234635
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Recent Developments in the Separation of Low Molecular Weight Heparin Anticoagulants.
    Sadowski R; Gadzała-Kopciuch R; Buszewski B
    Curr Med Chem; 2019; 26(1):166-176. PubMed ID: 28982317
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process.
    Kesselheim AS; Gagne JJ; Franklin JM; Eddings W; Fulchino LA; Campbell EG
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):694-701. PubMed ID: 28370652
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Indications and drugs for anticoagulation therapy in children.
    Andrew M
    Thromb Res; 1996; 81(2 Suppl):S61-73. PubMed ID: 8822129
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Update of the recommendations on biosimilar low-molecular-weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis.
    Harenberg J; Walenga J; Torri G; Dahl OE; Drouet L; Fareed J;
    J Thromb Haemost; 2013 Jul; 11(7):1421-5. PubMed ID: 23615078
    [No Abstract]   [Full Text] [Related]  

  • 73. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
    Simoens S; Huys I
    Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV).
    Imberti D; Marietta M; Polo Friz H; Cimminiello C
    Thromb J; 2017; 15():13. PubMed ID: 28490974
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Critical considerations into the new EMA guideline on bioequivalence.
    Marzo A; Fontana E
    Arzneimittelforschung; 2011; 61(4):207-20. PubMed ID: 21650079
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Analytical and statistical comparability of generic enoxaparins from the US market with the originator product.
    Mourier PA; Agut C; Souaifi-Amara H; Herman F; Viskov C
    J Pharm Biomed Anal; 2015 Nov; 115():431-42. PubMed ID: 26280926
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Regulatory considerations for generic or biosimilar low molecular weight heparins.
    García-Arieta A; Blázquez A
    Curr Drug Discov Technol; 2012 Jun; 9(2):137-42. PubMed ID: 21838658
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Low-molecular-weight heparins: a new generation of anticoagulants.
    Messerschmidt K
    S D J Med; 1998 Feb; 51(2):47-8. PubMed ID: 9509889
    [No Abstract]   [Full Text] [Related]  

  • 80. Scientific considerations in the regulatory approval of generic (or biosimilar) version of enoxaparin sodium - A lifesaving carbohydrate polymer.
    Iqbal Z; Sadaf S
    Regul Toxicol Pharmacol; 2023 Sep; 143():105446. PubMed ID: 37532121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.